The primary purpose of this study is to help answer the following research questions:
- To assess whether Enzastaurin combined with rituximab, gemcitabine and oxaliplatin
(R-GEMOX) can help participants with Diffuse Large B-Cell Lymphoma (DLBCL) remain free
from disease and thus live longer.
- To assess for any side effects that might be associated with enzastaurin and R-GEMOX .
- To look at the characteristics and levels of certain genes and proteins to learn more
about DLBCL and how enzastaurin works in the body.
- To look at the level of enzastaurin in the body and how long it remains.